Last Updated

26 Jul 2023

Technical consultation to review the effectiveness of rectal artesunate used as pre-referral treatment of severe malaria in children

Click on the image above to open the resource: 

Technical consultation to review the effectiveness of rectal artesunate used as pre-referral treatment of severe malaria in children

WHO has recommended rectal artesunate (RAS) as an effective pre-referral treatment for severe malaria since 2006. On 18-19 October 2022, WHO convened a meeting with independent experts to review the evidence from effectiveness studies of RAS and develop guidance for the safe and effective implementation of this intervention.

External Reference
WHO publication

Related Resources
Guidance & Strategy
|

The use of rectal artesunate as a pre-referral treatment for severe Plasmodium falciparum malaria, 2023 update

World Health Organization (WHO)

Guidance & Strategy
|

The use of artesunate-pyronaridine for the treatment of uncomplicated malaria: Information note

World Health Organization (WHO)

Related Projects

- | $394k

Aiming at prolonging the therapeutic lifespan of artemisinin-based combination therapies in an era of imminent Plasmodium falciparum resistance in East-Africa - new strategies with old tools
Swedish Research Council (SRC), Sweden, Uppsala University | Andreas Mårtensson, Billy Ngasala | Tanzania, Sweden
- | $421k

Optimising dosing of dihydroartemisinin-piperaquine for malaria preventive treatment in Malawian infants
Wellcome Trust, UK, Liverpool School of Tropical Medicine (LSTM), UK | Clifford George Banda | Malawi
Themes
Vulnerable Populations
Health Systems & Op. Research
Drug-based Strategies
Author(s)
World Health Organization (WHO)

Date Published